PFIZER INC

Pfizer’s Q1 earnings reveal oncology & obesity growth, cost‑saving plans, and a shift from COVID‑19 sales, boosting share price and long‑term prospects.

Explore Pfizer’s latest corporate moves—from phantom stock exercises to global licensing deals—and learn how these actions impact investor value, governance, and litigation risks.

Pfizer’s first‑half earnings show strong revenue, high‑margin launches and a resilient pipeline that mitigates patent cliffs, positioning the pharma giant for growth and strategic M&A.

Pfizer insider trades show routine activity while earnings grow on diversified non‑COVID drugs and cost cuts—insight into how the pharma leader stays ahead of patent risks.

Pfizer’s Q2 2026 earnings reveal a 12.3% revenue lift and $2.4B net profit, driven by oncology and obesity wins, strong market‑access contracts, and a focused M&A strategy to sustain growth.

Pfizer beats Q2 earnings, lifts full‑year revenue outlook to $61‑$62 B, driven by strong anticoagulant and oncology sales amid shrinking COVID‑product demand.

Explore how Pfizer’s Q2 2026 earnings reveal the impact of patent expirations, COVID‑19 sales decline, and its new oncology/obesity pipeline.

Discover why investors are watching Pfizer’s upcoming earnings, from revenue trends to oncology growth, and how it signals the health of the pharma sector.

Explore how Pfizer’s latest earnings, patent cliffs, and biosimilar strategy shape its growth outlook in today’s pharma market.

EU approves Pfizer‑BioNTech’s new mRNA COVID‑19 vaccine—boosting sales, margins and strategic positioning amid variant‑driven demand and competitive pressures.